Adavosertib (MK-1775)

Catalog No.S1525

Adavosertib (MK-1775) Chemical Structure

Molecular Weight(MW): 500.6

MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 270 In stock
USD 470 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 29 Publications

Purity & Quality Control

Choose Selective Wee1 Inhibitors

Biological Activity

Description MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Features The first reported Wee1 inhibitor.
Targets
Wee1 [1]
(Cell-free assay)
5.2 nM
In vitro

MK-1775 inhibits Wee1 kinase in an ATP-competitive manner. Compared to Wee1, MK-1775 displays 2- to 3-fold less potency against Yes with IC50 of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibits cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibits the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with EC50 of 49 nM, and suppresses gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest in a dose-dependent manner, with EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. MK-1775 treatment alone at 30-100 nM has no significant antiproliferative effect in WiDr and H1299 cells, whereas MK-1775 at 300 nM, sufficient to inhibit Wee1 by >80%, displays moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
ASPC-1 NIH0b|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPCeYNKSzVyPUGzMlIhyrFiMT6xJO69VQ>? MmjnNlU1PTh7NUS=
BxPC-3 NIf1cpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrUNpJMUUN3ME2wMlghyrFiMD6wN{DPxE1? MkjpNlU1PTh7NUS=
CFPAC-1 NH;GfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRS5VKSzVyPUOuN{DDuSByLkKg{txO M4DEW|I2PDV6OUW0
HPAC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[yNmlEPTB;MD61JOKyKDBwMEGg{txO NI[xe2ozPTR3OEm1OC=>
MIAPaCa-2 M1XIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLRUlExUUN3ME2wMlUhyrFiMD6wOUDPxE1? MoT6NlU1PTh7NUS=
PANC-1 NUTCdFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf4[I1kUUN3ME2xNE43KMLzIEGuNUDPxE1? MVGyOVQ2QDl3NB?=
SK-N-BE (2) MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwNPMAjeKy6oDLMD6zJO69VQ>? M4r4ZVI2OzB6OUG2
SK-N-BE (2), PAN→MK M{K3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7zfnRCUUN3ME2yOk436oDLwsJihKk6NjZizszN MlG4NlU{ODh7MU[=
SK-N-BE (2), MK→PAN NHPtbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPXlRnUUN3ME2yMlTjiIoEsfMAjVAvOyEQvF2= NEThV2ozPTNyOEmxOi=>
SK-N-AS Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrDVWxKSzVyPUCuOVDjiIoEsfMAjVAvODJizszN NGHNS5MzPTNyOEmxOi=>
SK-N-DZ M1HQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\aTWM2OD1yLkO25qCKyrIkgJmwMlAyKM7:TR?= NVfSeY0yOjV|MEi5NVY>
SK-N-AS Ml\IRZBweHSxc3nzJGF{e2G7 M4\ZUlUxOCCwTR?= NH3QWmI1QCCq M3HHZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFW0[W8zPTNyOEmxOi=>
SK-N-DZ M2rzcmFxd3C2b4Ppd{BCe3OjeR?= MXq1NFAhdk1? M37KNFQ5KGh? MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3:4OFI2OzB6OUG2
THP-1 NEe2TZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xNVI2NzJ3MD:1NFAhdk1? NE\LPGc1QCCq M3S0V4lv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NEjpNXEzPTB6NE[xOC=>
MV4-11 Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorMNVI2NzJ3MD:1NFAhdk1? NW\iWZgxPDhiaB?= NGi4VmNqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M4iwNVI2ODh2NkG0
U937 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuzWVJ3OTJ3L{K1NE82ODBibl2= NWXXTHVtPDhiaB?= NIDVemZqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NVzuNIJkOjVyOES2NVQ>
HL-60 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LZV|EzPS9{NUCvOVAxKG6P NVzyeIRJPDhiaB?= M{HKWolv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NXvme3lYOjVyOES2NVQ>
OCI-AML3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEezR5IyOjVxMkWwM|UxOCCwTR?= NXvxW5EyPDhiaB?= MoP1bY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NILWemEzPTB6NE[xOC=>
MOLM-13 M3[4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljrNVI2NzJ3MD:1NFAhdk1? M{POSVQ5KGh? MXHpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MmXtNlUxQDR4MUS=
CMK MlqxR4VtdCCYaXHibYxqfHliQYPzZZk> MV:xNE0yODByMDDuUS=> MkDPO|IhcA>? MXny[YR2[2W|IHPlcIwhfmmjbHnibZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M2q2bFI1QTZ{M{Ox
CMY NET6VnlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWjMWmFROTBvMUCwNFAhdk1? NFfrV3Q4OiCq M1L2WpJm\HWlZYOgZ4VtdCC4aXHsbYJqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MYiyOFk3OjN|MR?=
Dayo NIPJR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGeydVlKSzVyPUG1NEBvVQ>? M4C5R|I1PjZzOUGw
UW228 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULnUpFiUUN3ME2yN|Ihdk1? M4rJSlI1PjZzOUGw
IST-MES1 NInubGVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkWyNVUxNzJ3MDDuUS=> NEPXXoQ4OiCq MmLN[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M1TtUVI1OzZ3N{iy
IST-MES2 M1:yeGNmdGxiVnnhZoltcXS7IFHzd4F6 MYWxOVAwOjVyIH7N NFvJXZE4OiCq NUDWOpJL\W6qYX7j[ZMhfGinIHPpd5Bt[XSrbjDjfZRwfG:6aXOg[YZn\WO2IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MViyOFM3PTd6Mh?=
REN NUfNb41MS2WubDDWbYFjcWyrdImgRZN{[Xl? MontNVUxNzJ3MDDuUS=> MWS3NkBp MlTn[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M4m4dVI1OzZ3N{iy
NCI-H2452 M{C3b2NmdGxiVnnhZoltcXS7IFHzd4F6 MU[xOVAwOjVyIH7N MV23NkBp NGPlRmlmdmijbnPld{B1cGViY3nzdIxifGmwIHP5eI91d3irYzDl[oZm[3RiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M1vZS|I1OzZ3N{iy
MSTO-211H MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXyxOVAwOjVyIH7N M4fMbVczKGh? NXT3W|dD\W6qYX7j[ZMhfGinIHPpd5Bt[XSrbjDjfZRwfG:6aXOg[YZn\WO2IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MkXuNlQ{PjV5OEK=
NCI-H2052 MkC1R4VtdCCYaXHibYxqfHliQYPzZZk> MYixOVAwOjVyIH7N NX7BU3ZxPzJiaB?= MlzH[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M2f4O|I1OzZ3N{iy
WEE1 NXzj[|BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLjdYRKSzVyPUWuNkBvVQ>? Mn3ZNlM3QTl4NUW=
CDC2 M{jBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|Ux97zgMUCwNEBvVQ>? M1;3e|I{Pjl7NkW1
CDK7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|Ux97zgMUCwNEBvVQ>? MXiyN|Y6QTZ3NR?=
MYT1 NGHpSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTV|MDDuUS=> MUGyN|Y6QTZ3NR?=
T98G  MoHkRZBweHSxc3nzJGF{e2G7 M1m1RlExOC9{NUCgcm0> NHS1Z403KGh? NVPJUnNI\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDrbYxtcW6p M3vlSVIyQTl{N{mz
A549 NIm2OIJCeG:ydH;zbZMhSXO|YYm= M4XmUVIxOCCwTR?= M{LJXFEhcA>? MXfyZYRqd3OnboPpeIl7\XNiTmPDUGMh[2WubIOgbY4h[SCyNUOt[IVx\W6mZX70JI1idm6nch?= MlXHNlE4QTlyM{O=
H460 NWHLZZQzSXCxcITvd4l{KEG|c3H5 MnHONlAxKG6P M3nMUlEhcA>? NGnoOIRz[WSrb4PlcpNqfGm8ZYOgUnNEVENiY3XscJMhcW5iYTDwOVMu\GWyZX7k[Y51KG2jbn7ldi=> NFHPfXczOTd7OUCzNy=>
H1299 NUHSPFlsSXCxcITvd4l{KEG|c3H5 NG\UbYszODBibl2= MoXzNUBp MYfyZYRqd3OnboPpeIl7\XNiTmPDUGMh[2WubIOgbY4h[SCyNUOt[IVx\W6mZX70JI1idm6nch?= MYKyNVc6QTB|Mx?=
Calu-6  NHvWfYlCeG:ydH;zbZMhSXO|YYm= MVWyNFAhdk1? MUixJIg> NFuwc2pz[WSrb4PlcpNqfGm8ZYOgUnNEVENiY3XscJMhcW5iYTDwOVMu\GWyZX7k[Y51KG2jbn7ldi=> NXyzS|hkOjF5OUmwN|M>
WiDr MlTOT4lv[XOnIFHzd4F6ew>? NULFXYd6OTBvMUCwNFAhdk1? NVrTPIJuQCCq MWDpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gR2REOiCjdDDUfZIyPSC5aYToJIFvKEWFNUFCpJZidHWnIH;mJFg2KG6vb3yvUEBxemW2cnXheIVlKHerdHig[4Vu[2m2YXLpcoU> MojJNVk5QDd3NEW=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Cdk1(Y15) / Cdk1; 

PubMed: 25609063     


The impact of a 24 hour pre-treatment of MK-1775 on p-Cdk1 was assessed by western blotting. Because of low basal phosphorylation, GBM22 was irradiated (RT) with 10 Gy.

p-KAP1(S824) / p-Chk2(T68) / p-Chk1(S345); 

PubMed: 25609063     


Western blot evaluation of GBM6 and GBM22 short-term explant cultures 24 hours after treatment with either MK-1775 or TMZ or the combination. 

PARP / CF-PARP / pH3(S10) / p-CDC25c(S216) / p-CDK2(Y15); 

PubMed: 25458954     


Pancreatic cancer cells were treated with vehicle control or 500 nM MK-1775 for 48 h. Whole cell lysates were subjected to Western blotting and probed with anti-PARP, -p-H3, -γH2AX, -p-CHK1, -CHK1, -p-CDC25C, -p-CDK1, - CDK1, -p-CDK2, -CDK2, or -β-actin antibody.

WEE1; 

PubMed: 27616351     


MIA PaCa2, PANC-1, Hs 766T, Capan-1 and PL11 cells were treated with MK-1775 (400 nM/L) and/or MMC (150 nM/L) for 24 hours. Whole cell lysates were prepared using RIPA and western blot was performed to assess the protein expression of WEE1 (90 kDa), pCDK1(y15) (34 kDa), CDK1 (34 kDa) and GAPDH (36 kDa) as loading control. 

25609063 25458954 27616351
Immunofluorescence
tubulin / p-HH3(S10); 

PubMed: 30755439     


FaDu and UNC7 cells were treated with adavosertib (500 nM), alisertib (250 nM), or adavosertib + alisertib for 24 hours and followed by immunofluorescent staining with anti-tubulin (Green) and anti-pHH3 (S10; Red). Nucleus was stained with DAPI. (A) Representative images of mitotic cells were captured by confocal microscopy. Scale bar: 10 µm.

γH2AX; 

PubMed: 25609063     


A) γH2AX foci formation in GBM6 and GBM22 were assessed 24 h after a single treatment of 300 nM MK-1775. 

Cleaved caspase-3 / pH3; 

PubMed: 27616351     


MIA PaCa2 cells were treated and dual stained with pH3 to observe mitotic entry; and cleaved caspase 3 (CL-CSP3) to observe caspase 3 activity.

30755439 25609063 27616351
Growth inhibition assay
Cell viability; 

PubMed: 25458954     


Pancreatic cancer cell lines were cultured in 96-well plates at 37℃ for 48 h in complete medium with variable concentrations of MK-1775 and viable cell numbers were determined using MTT reagent and a microplate reader. The data are presented as means ± standard errors from at least 3 independent experiments.

IC50; 

PubMed: 25084614     


AML cell lines were cultured for 72 h in complete medium with variable concentrations of MK-1775 (MK) and viable cell numbers were determined using MTT assays. IC50 values were calculated as drug concentration necessary to inhibit 50% growth compared to untreated control cells.

25458954 25084614
In vivo MK-1775 treatment alone at ~20 mg/kg displays minimal antitumor effects against WiDr xenografts in rats with T/C of 69% at day 3. Antitumor efficacy by MK-1775 alone in the nude rat HeLa-luc and TOV21G-shp53 xenograft models is also moderate. [1]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

Recombinant human Wee1 is used. Kinase reaction is conducted with 10 μM ATP, 1.0 μCi of [γ-33P]ATP, and 2.5 μg of poly(Lys, Tyr) as a substrate in the presence of increasing concentrations of MK-1775 at 30°C for 30 minutes. Radioactivity incorporated into the substrate is trapped on MultiScreen-PH plates and is counted on a liquid scintillation counter.
Cell Research:

[1]

+ Expand
  • Cell lines: WiDr, NCI-H1299, TOV21G, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are treated with or without gemcitabine for 24 hours, then with MK-1775 for an additional 24 hours. Cell viability is determined with a WST-8 kit using SpectraMax. Cellular caspase-3/7 activities are determined with a Caspase-3/7 Glo kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Immunodeficient nude rats (F344/NJcl-rnu) bearing WiDr, HeLa-luc, or TOV21G-shp53 tumors
  • Formulation: Prepared in a vehicle of 0.5% methylcellulose solution
  • Dosages: ~20 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (159.8 mM)
Ethanol 10 mg/mL (19.97 mM)
Water 0.0001 mg/mL (0.0 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 500.6
Formula

C27H32N8O2

CAS No. 955365-80-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02037230 Active not recruiting Adenocarcinoma of the Pancreas University of Michigan Rogel Cancer Center January 2014 Phase 1|Phase 2
NCT02037230 Active not recruiting Adenocarcinoma of the Pancreas University of Michigan Rogel Cancer Center January 2014 Phase 1|Phase 2
NCT01748825 Active not recruiting Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 19 2012 Phase 1
NCT01748825 Active not recruiting Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 19 2012 Phase 1
NCT01357161 Completed Ovarian Cancer Merck Sharp & Dohme Corp. July 26 2011 Phase 2
NCT01357161 Completed Ovarian Cancer Merck Sharp & Dohme Corp. July 26 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare MK1775 methylcellulose solution? and how to prepare methylcellulose itself? Once make the MK1775 methylcellulose solution, how should i keep it?

  • Answer:

    MK1775 in 0.5% methylcellulose is a suspension or emulsion, and it is ok to treat mice orally. It is recommended to dissolve methylcellulose in saline. It will take some time to dissolve methylcellulose, and you can vortex it for a while. The MK1775 methylcellulose solution can be stored at 4°C for a week.

Wee1 Signaling Pathway Map

Related Wee1 Products0

Tags: buy Adavosertib (MK-1775) | Adavosertib (MK-1775) supplier | purchase Adavosertib (MK-1775) | Adavosertib (MK-1775) cost | Adavosertib (MK-1775) manufacturer | order Adavosertib (MK-1775) | Adavosertib (MK-1775) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID